Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CAO Sells $17,410.31 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Huizenga sold 1,283 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $13.57, for a total transaction of $17,410.31. Following the transaction, the chief accounting officer owned 67,863 shares of the company’s stock, valued at approximately $920,900.91. The trade was a 1.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Theodore Alan Huizenga also recently made the following trade(s):

• On Thursday, September 3rd, Theodore Huizenga sold 161 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $13.99, for a total value of $2,252.39.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $14.50 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $12.73 and a one year high of $39.89. The company has a market cap of $1.43 billion, a P/E ratio of -2.48 and a beta of 0.31. The business’s 50-day simple moving average is $24.26 and its 200-day simple moving average is $24.49.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The firm had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The firm’s quarterly revenue was up 28.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.17) earnings per share. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -3.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Evercore lowered shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 price target on the stock. in a research note on Thursday, September 3rd. Wall Street Zen raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Guggenheim reduced their target price on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, August 4th. Robert W. Baird cut Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $40.00 to $16.00 in a research report on Thursday, September 3rd. Finally, William Blair downgraded Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.63.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds have recently made changes to their positions in RARE. BlackRock Inc. acquired a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $355,746,000. Assenagon Asset Management S.A. increased its holdings in shares of Ultragenyx Pharmaceutical by 1,030.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after purchasing an additional 2,057,951 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $38,347,000. GW&K Investment Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 19.6% in the fourth quarter. GW&K Investment Management LLC now owns 1,375,407 shares of the biopharmaceutical company’s stock valued at $31,634,000 after purchasing an additional 225,238 shares during the period. Finally, Jefferies Financial Group Inc. purchased a new stake in Ultragenyx Pharmaceutical during the second quarter worth about $31,040,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Major regulatory milestone: FAYUVI is Ultragenyx’s second approved gene therapy and sixth FDA-approved product, creating a new commercial opportunity in an ultra-rare disease with an estimated 3,000 to 5,000 patients in commercially accessible markets. Reuters FDA approval article
• Positive Sentiment: Clinical support and potential revenue catalyst: In the pivotal Transpher A study, treated patients showed a 23.5-point cognitive-score advantage versus an untreated natural-history cohort, with follow-up extending nearly eight years. Commercial shipments to qualified treatment centers are expected within 30–60 days. Ultragenyx FAYUVI approval release
• Positive Sentiment: Ultragenyx also received a Priority Review Voucher, which could be used to accelerate a future drug application or potentially monetized. Its UltraCare program is intended to help families navigate insurance and treatment access.
• Neutral Sentiment: The approval follows a sharp selloff tied to a failed Angelman syndrome trial. Analysts’ views remain mixed: the reported consensus rating is “Moderate Buy,” but price targets have been reduced substantially, with recent targets ranging from $16 to $74. RARE selloff article
• Negative Sentiment: FAYUVI carries significant gene-therapy risks, including elevated liver enzymes, thrombocytopenia, infusion reactions, possible thrombotic microangiopathy and a potential malignancy risk. Insurance coverage, reimbursement, treatment-center capacity and manufacturing execution could limit the pace of the launch.
• Negative Sentiment: A shareholder law firm announced an investigation into potential claims involving Ultragenyx, while company insiders have reported multiple stock sales and no purchases during the past six months. Pomerantz investor alert

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.